Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.81
0.00 (0.07%)
Nov 6, 2026, 4:00 PM EST - Market closed
Evolus Revenue
Evolus had revenue of $77.95M in the quarter ending September 30, 2026, with 13.03% growth. This brings the company's total for the last twelve months to $325.47M, up 13.87% year-over-year. In the year 2025, Evolus had annual revenue of $297.18M with 11.61% growth. That makes Evolus the 13,963rd largest company in the world by revenue and 2,563rd in the United States.
Revenue (ttm)
$325.47M
Revenue Growth
+13.87%
P/S Ratio
1.38
Revenue / Employee
$891,707
Employees
365
Market Cap
450.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 297.18M | 30.90M | 11.61% |
| Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
| Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
| Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
| Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
| Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
| Dec 31, 2019 | 34.93M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 963.10M |
| Evotec SE | 815.72M |
| Collegium Pharmaceutical | 815.19M |
| Emergent BioSolutions | 649.10M |
| Ironwood Pharmaceuticals | 400.30M |
| Aurora Cannabis | 221.16M |
| Canopy Growth | 217.18M |
| Kamada | 191.85M |
EOLS News
- 3 days ago - Evolus price target raised to $15 from $13 at BTIG - TheFly
- 4 days ago - Evolus reports Q3 EPS (19c), consensus (7c) - TheFly
- 4 days ago - Evolus backs FY26 revenue view $330M-$337M, consensus $334.15M - TheFly
- 4 days ago - Evolus Earnings Call Transcript: Q3 2026 - Transcripts
- 4 days ago - Evolus Earnings release: Q3 2026 - Filings
- 4 days ago - Evolus Slides: Q3 2026 - Filings
- 4 days ago - Evolus Quarterly report: Q3 2026 - Filings
- 4 days ago - Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook - Business Wire